SCHEMBL63443

SCHEMBL63443

COCC1(C(=O)NC23CCC(CC2)Cn2c3nc(C(=O)NCc3ccc(F)c(C)c3)c(O)c2=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.38
CYP2C9 P11712 1/20 0.38
MMP13 P45452 10/20 0.37
MMP10 P09238 5/20 0.34
MMP8 P22894 5/20 0.34
SSTR1 P30872 1/20 0.33
SSTR4 P31391 1/20 0.33
KCNE1 P15382 1/20 0.33
CCR1 P32246 1/20 0.33
KCNQ1 P51787 1/20 0.33
MMP9 P14780 1/20 0.32
PDE10A Q9Y233 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
PTPN7 P35236 1/20 0.31
DUSP3 P51452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL64242 0.88 MMP13 (0.39) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL64434 0.87 MMP13 (0.38) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL51959 0.86 CYP2C9 (0.39) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL62253 0.86 MMP13 (0.37) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL52059 0.86 CYP2C9 (0.45) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL63887 0.85 MMP13 (0.37) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL64237 0.84 MMP13 (0.40) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL64216 0.84 HCRTR1 (0.39) KCNH2CYP2C9MMP13ALDH1A1
SCHEMBL53073 0.84 KCNH2 (0.40) KCNH2CYP2C9MMP13MMP10MMP8
SCHEMBL62611 0.83 KCNH2 (0.38) KCNH2CYP2C9MMP13MMP10MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885MMP13 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.